ClinicalTrials.gg
TerminatedNCT03461952NIMBLeUpdated Feb 22, 2024Results posted

Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)

A Phase 2 interventional study of Nivolumab and Ipilimumab in Advanced Solid Tumors, sponsored by Canadian Cancer Trials Group. Terminated at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-22.

Sponsored by Canadian Cancer Trials Group · Phase 2, Interventional, and Treatment

Why this study was terminated
cfDNA screening data found that the prevalence of POLE/POLD1 mutations was lower than expected. It was determined that there are no feasible options to amend this study in a fashion that would not be duplicative of other currently accruing trials.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
4
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine the safety and effectiveness of nivolumab alone or in combination with ipilimumab in patients with metastatic or unresectable tumors harbouring mutations in genes, POLE and POLD1. These mutations will be determined by plasma cfDNA. Nivolumab and ipilimumab have been given to patients across multiple types of cancer, and safe doses and schedules have been determined.

Read the detailed description

Participants in this study have been diagnosed with metastatic or unresectable solid tumors that have a mutation in POLE and/or POLD1. Nivolumab alone or in conjunction with ipilimumab is predicted to be effective against tumors with POLE and/or POLD1 mutations as these genetic changes cause increased rates of mutations in the DNA of tumor cells. These high mutation rates have been associated with response to immunotherapy agents such as nivolumab and ipilimumab.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Canadian Cancer Trials Group is the lead sponsor of 93 studies on the registry; 29 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have confirmed advanced ( or unresectable) solid tumors.
  • Patients must have received at least 1 standard cancer therapy for their tumor type and progressed on their most recent regimen; patients may be treatment naïve if they refuse standard treatment or there is no standard treatment for their cancer.
  • Prior /neoadjuvant therapy with curative intent is considered a prior therapy if disease recurrence occurs within at least 6 months.
  • Patients may not have received prior immunotherapy
  • Patients must consent to blood collection for testing after registration by a central reference laboratory.
  • Patients must have clinically and/or radiologically documented disease with at least one lesion measurable as defined by 1.1.
  • Patients must be ≥ 18 years of age.
  • performance status 0 or 1.
  • Patients must have adequate hematology and organ function
  • Patient consent for screening must be appropriately obtained in accordance with applicable local and regulatory requirements.
  • Patients must have solid tumors that demonstrate POLE or POLD1 mutations identified at study entry via plasma cfDNA testing or tumor tissue testing for POLE and POLD1 mutations. A CLIA-certified testing of tumor tissue demonstrating POLE or POLD1 mutation can qualify for eligibility and randomization, however, plasma will be submitted for central cfDNA testing. In the event of discordance between tissue and central laboratory testing, the patient will continue in study but will not be included in the primary analysis. These patients will however be included in the secondary analysis.
  • Patients must have recovered to ≤ grade 1 from all reversible toxicity related prior systemic or radiation therapy and have a 2 weeks washout.
  • Previous major surgery is permitted provided that it has been at least 28 days prior to patient registration and that wound healing has occurred.
  • White Blood Cells ≥ 2.0 x 109/L (2000/µL)
  • Absolute neutrophils ≥ 1.5 x 109/L (1500/µL)
  • ≥ 100 x 10\^9/L (100 x103/µL)
  • ≥80 g/L* (8.0 g/dL)
  • ≤ 1.5 x (upper limit of normal)**
  • and/or ALT ≤ 3 x ULN
  • Serum creatinine ≤ 1.5 x ULN or: ≥40 mL/min
  • Patients must be willing to consent to provision of
  • Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements
  • Patients must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the trial.
  • In accordance with CCTG policy, protocol treatment is to begin within 2 working days of patient randomization.
  • Women of (WOCBP) and men who are sexually active with WOCBP must have agreed to use a highly effective method

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of other untreated or malignancies, which required therapy within the past 2 years. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen may be eligible after consultation with the CCTG.
  • Patients with primary CNS tumors are not eligible.
  • Patients with active or are not eligible. Patients with brain metastases are eligible if these have been treated and clinically stable. There must also be no requirement for doses of systemic (> 10 mg/day prednisone equivalents). Physiologic replacement doses of systemic corticoidsteroids are permitted, even if >10mg/day prednisone equivalents
  • History of primary immunodeficiency, history of allogenic organ transplant that requires therapeutic immunosuppression and the use of immunosuppressive agents within 14 days of study drug administration*
  • Active or prior documented or inflammatory disorders. Including, inflammatory bowel disease (e.g. colitis or Crohn's disease), diverticulitis with the exception of diverticulosis, celiac disease or other serious gastrointestinal chronic conditions associated with diarrhea), systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome (granulomatosis with polyangiitis), rheumatoid arthritis, hypophysitis, uveitis, etc., within the past 3 years prior to the start of treatment. Patients with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions considered to be of low risk for recurrence are permitted to enroll.
  • History of to nivolumab or ipilimumab or any .
  • Any previous treatment with a or anti-PD-L1, anti-PD-L2 inhibitor, including nivolumab or an anti-CTLA4, including ipilimumab, or drug specifically targeting T-cell stimulation or immune checkpoint pathways.
  • Patients with serious illnesses or medical conditions which would not permit the patient to be managed according to the protocol (including corticosteroid administration), or would put the patient at risk. This includes but is not limited to:

    • History of significant neurologic or psychiatric disorder which would impair the ability to obtain consent or limit compliance with study requirements.
    • Active infection requiring systemic therapy; (including any patient known to have active , or (HIV) or tuberculosis or any infection requiring systemic therapy).
    • Active peptic ulcer disease or gastritis
    • Active pneumonitis.
  • Patients receiving concurrent treatment with other anti-cancer therapy or other investigational anti-cancer agents.
  • Patients who have experienced untreated and/or uncontrolled cardiovascular conditions and/or have symptomatic cardiac dysfunction (unstable angina, congestive heart failure, myocardial infarction within the previous year or cardiac ventricular arrhythmias requiring medication, history of 2nd or 3rd degree atrioventricular conduction defects).
  • Pregnant or lactating women.
  • Men who are sexually active with women of and women of childbearing potential must agree to use adequate .
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Nivolumab

    240mg Q2W

    Drug: Nivolumab

  • Experimental
    Nivolumab + Ipilimumab

    Nivolumab 240mg Q2Wk + Ipilimumab 1mg/kg Q6W

    Drug: Nivolumab · Drug: Ipilimumab

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate by RECIST 1.1

    Objective Response Rate by RECIST 1.1: CR, PR, SD, or PD

    Time frame: 36 months

Secondary outcomes

  1. Efficacy as Measured by Objective Response Rate

    Will be reported using percentages over all randomized patients with 90% exact confidence intervals

    Time frame: 36 months

  2. Duration of Response

    Response rates will be reported using percentages over all patients who have received at least one dose of treatment with 90% exact CI of each arm in a non-comparative analysis

    Time frame: 36 months

  3. Number and Severity of Adverse Events Using CTCAE 5.0

    AE rates will be reported using percentages with 90% exact CI

    Time frame: 36 months

  4. Correlation Between POLE or POLD1 Mutations in Tumor and POLE or POLD1 Mutations in Blood

    Correlation between POLE or POLD1 mutations in tumor and POLE or POLD1 mutations in blood: Will be assessed by Fischer's exact test in each arm

    Time frame: 36 months

  5. To Evaluate Response by iRECIST

    iRECIST: iCR, iPR, iSD, iUPD, iUPD/PD

    Time frame: 36 months

07

Results

Posted Feb 22, 2024

Participant flow

Participant flow — Overall Study
MilestoneNivolumabNivolumab + Ipilimumab
Started22
Completed22
Not completed00

Outcome measures

PrimaryObjective Response Rate by RECIST 1.1

Objective Response Rate by RECIST 1.1: CR, PR, SD, or PD

Time frame:
36 months
Reported as:
Count of participants · Participants
Objective Response Rate by RECIST 1.1
ParticipantsNivolumabNivolumab + Ipilimumab
Objective Response Rate by RECIST 1.1NANA
SecondaryEfficacy as Measured by Objective Response Rate

Will be reported using percentages over all randomized patients with 90% exact confidence intervals

Time frame:
36 months
Reported as:
Count of participants · Participants
Efficacy as Measured by Objective Response Rate
ParticipantsNivolumabNivolumab + Ipilimumab
Efficacy as Measured by Objective Response RateNANA
SecondaryDuration of Response

Response rates will be reported using percentages over all patients who have received at least one dose of treatment with 90% exact CI of each arm in a non-comparative analysis

Time frame:
36 months
Reported as:
Count of participants · Participants
Duration of Response
ParticipantsNivolumabNivolumab + Ipilimumab
Duration of ResponseNANA
SecondaryNumber and Severity of Adverse Events Using CTCAE 5.0

AE rates will be reported using percentages with 90% exact CI

Time frame:
36 months
Reported as:
Count of participants · Participants
Number and Severity of Adverse Events Using CTCAE 5.0
ParticipantsNivolumabNivolumab + Ipilimumab
Number and Severity of Adverse Events Using CTCAE 5.0NANA
SecondaryCorrelation Between POLE or POLD1 Mutations in Tumor and POLE or POLD1 Mutations in Blood

Correlation between POLE or POLD1 mutations in tumor and POLE or POLD1 mutations in blood: Will be assessed by Fischer's exact test in each arm

Time frame:
36 months
Reported as:
Count of participants · Participants
Correlation Between POLE or POLD1 Mutations in Tumor and POLE or POLD1 Mutations in Blood
ParticipantsNivolumabNivolumab + Ipilimumab
Correlation Between POLE or POLD1 Mutations in Tumor and POLE or POLD1 Mutations in BloodNANA
SecondaryTo Evaluate Response by iRECIST

iRECIST: iCR, iPR, iSD, iUPD, iUPD/PD

Time frame:
36 months
Reported as:
Count of participants · Participants
To Evaluate Response by iRECIST
ParticipantsNivolumabNivolumab + Ipilimumab
To Evaluate Response by iRECISTNANA

Adverse events

Collected over 36 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nivolumab1/2 (50%)0/2 (0%)2/2 (100%)
Nivolumab + Ipilimumab0/2 (0%)0/2 (0%)2/2 (100%)
Most frequent other events
Most frequent other events
EventNivolumabNivolumab + Ipilimumab
ConstipationGastrointestinal disorders1/21/2
DiarrheaGastrointestinal disorders1/20/2
Abdominal painGastrointestinal disorders0/21/2

Baseline characteristics

Age, Continuous
Age, Continuous(years)NivolumabNivolumab + IpilimumabTotal
Median53 (31 to 75)53 (50 to 55)53 (31 to 75)
Sex: Female, Male
Sex: Female, Male(Participants)NivolumabNivolumab + IpilimumabTotal
Female011
Male213
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)NivolumabNivolumab + IpilimumabTotal
Count of participants——0
08

Study locations

6 sites
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Tom Baker Cancer Centre
    Calgary, Alberta T2N 4N2, Canada
  • BCCA - Vancouver Cancer Centre
    Vancouver, British Columbia V5Z 4E6, Canada
  • Juravinski Cancer Centre at Hamilton Health Sciences
    Hamilton, Ontario L8V 5C2, Canada
  • Ottawa Hospital Research Institute
    Ottawa, Ontario K1H 8L6, Canada
  • University Health Network
    Toronto, Ontario M5G 2M9, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in Jun 2021, 26 months.

Results were first posted in Feb 2024, 2 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2018
First posted
Mar 12, 2018
StartActual
Mar 11, 2019
Primary completionActual
Jun 1, 2021
CompletionActual
Feb 9, 2022
Results first posted
Feb 22, 2024
Last update
Feb 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03461952
Lead sponsor
Canadian Cancer Trials Group
Collaborators
Cancer Research Institute, New York City, Bristol-Myers Squibb, Personal Genome Diagnostics
Responsible party
Sponsor
First posted
Mar 12, 2018
Start date
Mar 11, 2019
Primary completion
Jun 1, 2021
Completion
Feb 9, 2022
Results posted
Feb 22, 2024
Last update
Feb 22, 2024

Study contacts

Naiyer Rizvi
study chair · Thoracic Oncology and Immunotherapeutics, Columbia University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Ipilimumab

Start the discussion